24th week of 2015 patent applcation highlights part 7 |
Patent application number | Title | Published |
20150157547 | SKIN LIGHTENING COMPOSITION - The present invention relates to a skin lightening composition and a method of lightening skin. The skin lightening is achieved using siRNA oligonucleotides which are able to achieve this using much lower concentration as compared to known chemical actives. | 2015-06-11 |
20150157548 | SULFATE-FREE OR SUBSTANTIALLY SULFATE-FREE PERSONAL CARE CLEANSING COMPOSITIONS - Disclosed are personal care cleansing compositions including:
| 2015-06-11 |
20150157549 | VISCOUS COMPOSITION - The purpose of the present invention is to provide a viscous composition which is capable of achieving a high viscosity over a pH range from acidic to weakly acidic conditions even in the presence of a polyvalent metal salt by means of an alkyl-modified carboxyl group-containing water-soluble copolymer. A viscous composition, which is obtained by adjusting the pH of a liquid composition that contains a specific alkyl-modified carboxyl group-containing water-soluble copolymer, a polyvalent metal salt and water to 7.0 or more with use of a base, and then adjusting the pH of the resulting liquid composition to 2.5-6.5 with use of a carboxylic acid and/or a phosphorus oxo acid, is able to have a high viscosity. | 2015-06-11 |
20150157550 | Conditioner Compositions with Increased Deposition of Polyacrylate Microcapsules - A conditioner composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair. The conditioner composition is based on the combination of anionic charged polyacrylate microcapsules, deposition aids, conditioner agents, and a carrier. | 2015-06-11 |
20150157551 | SKIN MOISTURIZER - Disclosed is a topical skin care composition and corresponding methods for its use comprising water, a cationic surfactant, an occlusive skin conditioning agent, a humectant skin conditioning agent, and a silicone containing compound. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin. | 2015-06-11 |
20150157552 | COSMETIC COMPOUNDS HAVING TIME-DELAYED ACTIVE INGREDIENT RELEASE - The invention relates to particles including, relative in each case to the particle weight, 30 to 90 wt. % of polyalphaolefin wax(es) and 10 to 70 wt. % of one or more cosmetic active agents, selected from fragrances, cooling active agents and mixtures of fragrances and cooling active agents, as well as to cosmetic compositions containing water and 0.01 to 10 wt. %, relative to the weight of the cosmetic composition, of one or more of the aforementioned particles. | 2015-06-11 |
20150157553 | NON-CARIOGENIC, SUGAR-FREE CONFECTIONERY COMPOSITIONS CONTAINING ANTI-PLAQUE COMPONENTS AND NATURAL TREE, PLANTS AND TEA EXTRACTS FOR ORAL AND SYSTEMIC HEALTH BENEFITS - Non-cariogenic sugar-free confectionery compositions which deliver anti-plaque components to the mouth for oral health benefits and also deliver nutrients for systemic health benefits; wherein such confectionery compositions comprise of: (i) a safe and effective amount of natural tree, plants and tea extracts selected from moringa, matcha green tea, green tea, chia and mixtures thereof; (ii) one or more anti-plaque component or components; (iii) one or more natural, non-cariogenic, tooth-friendly sweetener or mixtures of sweeteners; (iv) a suitable confectionery carrier and (v) less than 10% water. | 2015-06-11 |
20150157554 | COMPOSITION - A solid cosmetic composition includes (i) sugar; (ii) a vegetable fibre, a fruit fibre or mixture thereof; and (iii) a soap. The solid cosmetic composition is prepared by dehydrating a liquid composition including (i) sugar in an amount of 33.75 to 47 wt. %; (ii) a vegetable fibre, a fruit fibre or mixture thereof, in an amount of 3.75 to 4.75 wt. %; (iii) a soap in an amount of 20 to 75 wt. %; and (iv) water in an amount of 11 to 15 wt. %. The amounts are based on the total combined amount of the sugar, the fibre, the soap and the water. | 2015-06-11 |
20150157555 | POMEGRANATE BASED SKIN PROTECTANT AND TOPICAL APPLICATION - A cosmetic composition is provided having ingredients that may prevent signs or conditions of aging and/or damage in skin, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including pomegranate juice concentrate; pomegranate extract; pomegranate seed oil; and at least one pharmaceutically or cosmetically acceptable vehicle. | 2015-06-11 |
20150157556 | Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort - Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation and/or xerostomia. Preferred compositions and methods employ one or more plant pulp products and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred product components are isolated from a fruit and/or seed (e.g., grape, cranberry, blue berry, black berry, etc.), and where a second component is is preferably a freeze-dried pulp from a citrus fruit (e.g., lemon, orange, lime, grapefruit, tangerine, mandarin orange, ugli fruit, etc.) not containing peel or juice therein. | 2015-06-11 |
20150157557 | METHOD OF IMPROVING THE APPEARANCE OF AGING SKIN - A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and olive oil extract in combination to a target area of skin that exhibits a sign of aging skin, and compositions that include an effective amount of artichoke leaf extract and olive oil extract in combination. The composition is applied for a period of time sufficient to improve the appearance of the aging skin. | 2015-06-11 |
20150157558 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 2015-06-11 |
20150157559 | METHODS OF TREATMENT OF CANCER BY CONTINUOUS INFUSION OF COENZYME Q10 - The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates. | 2015-06-11 |
20150157560 | METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE - The present disclosure is drawn to a method of administering glyburide intravenously to a subject over a period of time as a first bolus administration of glyburide; a second bolus administration of glyburide, after the first bolus; and a first continuous infusion administration of glyburide, wherein the first continuous infusion is administered at a first rate of administration for a first period of time, after the second bolus administration of glyburide. | 2015-06-11 |
20150157561 | DRUG DELIVERY SYSTEM - Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin. | 2015-06-11 |
20150157562 | Hypotensive lipid-containing biodegradable intraocular implants and related implants - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2015-06-11 |
20150157563 | OCULAR COMPOSITION AND METHOD - An ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can contain a thiolated hyaluronic acid moiety cross-linked to a second moiety. The composition can be configured for placement in or on an eye of a subject to provide controlled release of the antibiotic to the eye. A method of treating or preventing an ocular disease can include providing an ocular composition and applying the ocular composition to a surface of an eye of a subject to provide controlled release of the antibiotic to the eye. The ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can include a thiolated hyaluronic acid moiety cross-linked to a second moiety. | 2015-06-11 |
20150157564 | METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS - Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein. | 2015-06-11 |
20150157565 | PULMONARY DELIVERY OF MRNA TO NON-LUNG TARGET CELLS - Compositions comprising mRNA formulated for pulmonary administration and related methods for delivery of the mRNA and/or encoded protein to a non-lung cell or tissue. The compositions and methods may be used to prevent or ameliorate the symptoms of diseases associated with the mRNA encoded protein. | 2015-06-11 |
20150157567 | INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST - The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices. | 2015-06-11 |
20150157568 | Treatment of Spasticity with Intrathecal Dantrolene - The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof. The administration can be through a chronical drug delivery device such as an intrathecal pump. | 2015-06-11 |
20150157569 | Stabilized All-Aqueous Emulsions and Methods of Making and Using Thereof - Methods for preparing all-aqueous emulsions, including stable emulsions or emulsions having high viscosity and/or ultra-low interfacial tension are described. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute (e.g., dispersed phase) with at least a second phase containing a second solute (e.g., continuous phase). The solutes are incompatible with each other. The electrostatic forces between the two phases induce the formation of droplets of a dispersed phase in a continuous phase. The dispersed and continuous phases contain oppositely charged molecules, such as surfactants or other macromolecules and colloids which stabilize the drops of the dispersed phase. Complex coacervation of the oppositely charged molecules or colloids at the interface of the two aqueous phases results in formation of a membrane or barrier which prevents coalescence or aggregation of the droplets. The membrane also prevents leakage of any encapsulated agents from the droplets. | 2015-06-11 |
20150157570 | TAILORED LIPOSOMES FOR THE TREATMENT OF BACTERIAL INFECTIONS - The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of | 2015-06-11 |
20150157571 | TARGETED LIPOSOMES IN CANCER THERAPY - The invention provides pharmaceutical compositions containing a vehicle for the targeted delivery of therapeutic and diagnostic agents for the treatment of hyperproliferative diseases. The targeting component of the vehicle is a cystine molecule that is coupled to the cargo component, which can be either a therapeutic or diagnostic agent or to a nanoparticle composition that contains the therapeutic agent or diagnostic. The invention also provides methods of treating hyperproliferative disorders by targeting hyperproliferative disease cells for the targeted delivery of a therapeutic or diagnostic agent. | 2015-06-11 |
20150157572 | PROLIPOSOMAL TESTOSTERONE FORMULATIONS - Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy. | 2015-06-11 |
20150157573 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 2015-06-11 |
20150157574 | METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET - An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 2015-06-11 |
20150157575 | Pharmaceutical Formulations Comprising Vilazodone - The present invention provides an immediate release oral dosage form comprising therapeutically effective amount of vilazodone or a salt thereof and at least one excipient. The dosage form includes 10 to 40 mg of vilazodone or a salt thereof, and is compressed in a tablet formulation. The tablet comprising 40 mg vilazodone or a salt thereof has a hardness of more than 9 kp and less than or equal to 14 kp. The tablet comprising 20 mg vilazodone or a salt thereof has a hardness of more than 8 kp and less than or equal to 12 kp, and the tablet comprising 10 mg vilazodone or a salt thereof has a hardness of more than 6 kp and less than or equal to 9 kp. | 2015-06-11 |
20150157576 | Core-Shell Capsules for Encapsulation of Particles, Colloids, and Cells - Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules. | 2015-06-11 |
20150157577 | MATRIX AND LAYER COMPOSITIONS FOR PROTECTION OF BIOACTIVES - The invention relates to matrix and layer compositions comprising a first polymer. The matrix and layer compositions are useful in the delivery of bioactives. In particular, the matrices and layers may have advantageous properties including mechanical properties and protection of bioactives and may also provide for pH-dependent release of a bioactive. | 2015-06-11 |
20150157578 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING - A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer. | 2015-06-11 |
20150157579 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 2015-06-11 |
20150157580 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES - This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity. | 2015-06-11 |
20150157581 | BENZYLAMINE CONTAINING COMPOSITIONS AND METHODS FOR APPETITE SUPPRESSION - Herbal compositions and techniques for suppressing appetite and managing weight are described. These compositions and techniques are based at least in part on beneficial results showing that benzylamine can suppress appetite. In at least one embodiment, a composition that includes an effective amount of benzylamine and an effective amount of at least one benzylamine enhancer may be utilized for appetite suppression. | 2015-06-11 |
20150157582 | METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION - This disclosure relates to methods administering erythrohydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed | 2015-06-11 |
20150157583 | Pharmaceutical Composition - Pharmaceutical compositions comprising a plurality of ingredients that synergistically provide an antimicrobial, analgesic, or wound healing characteristic. | 2015-06-11 |
20150157584 | INHIBITORS OF HIPPO-YAP SIGNALING PATHWAY - This invention provides methods of preventing, reducing, delaying or inhibiting the proliferation, growth, migration and/or metastasis of cancer by administering an effective amount of an inhibitor of the Hippo-YAP signaling pathway. | 2015-06-11 |
20150157585 | PHARMACEUTICAL COMPOSITIONS - Implementations of a pharmaceutical composition used to help treat pain, reduce inflammation and fatigue, provide vital nutrients, and increase alertness in humans are provided. In some implementations, the pharmaceutical composition can be comprised of an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a multivitamin supplement, and an effective amount of caffeine sufficient to increase alertness, metabolic activity, and/or stave off drowsiness. The pharmaceutical composition can be formulated with any suitable nontoxic pharmaceutically acceptable inert carry material known to those skilled in the art and administered orally. | 2015-06-11 |
20150157586 | PENETRATING PHARMACEUTICAL FOAM - The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration. | 2015-06-11 |
20150157587 | COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE - Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein. | 2015-06-11 |
20150157588 | Pharmaceutical Composition Comprising Amino-Phenyl-Acetic Acid Octadec-(Z)-9-enyl Ester and Use Thereof for Treating Tumors - The present invention relates to the compound amino-phenyl-acetic acid octadec-(Z)-9-enyl ester, an enantiomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it, for use in the treatment of tumors and metastases, and to methods for treating a tumor or metastases comprising administering said compound to a subject in need thereof. The present invention particularly relates to said compound when it is dissolved in an ethanol solution. | 2015-06-11 |
20150157589 | COMPOSITIONS COMPRISING PYRUVATE ALKYL ESTERS AND USES THEREOF - The present invention provides a composition comprising pyruvic acid alkyl ester for ingestion by a human as a food, oral supplement or pharmaceutical. | 2015-06-11 |
20150157590 | COCRYSTALS OF (N,N-DIETHYLCARBAMOYL)METHYL METHYL (2E)BUT-2-ENE-1,4-DIOATE - Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate. | 2015-06-11 |
20150157591 | Compositions, Methods and/or Devices For Prevention and/or Treatment Of Dry Eye Disorders - The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C | 2015-06-11 |
20150157592 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2015-06-11 |
20150157593 | METHODS OF REDUCING LDL-P - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing LDL-P comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2015-06-11 |
20150157594 | ANTIBACTERIAL MICROELEMENT CHELATES AND THE USE THEREOF IN ANIMAL FEEDS - The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming. | 2015-06-11 |
20150157595 | METHODS OF TREATING A SUBJECT WITH BENIGN PROSTATE HYPERPLASIA - The invention generally relates to methods of treating a male subject with a prostate condition, for example, benign prostate hyperplasia (BPH). In certain embodiments, the invention provides methods of treating a male subject with a prostate condition, which include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis. | 2015-06-11 |
20150157596 | METHODS OF INDUCING SEDATION - The present invention provides methods for determining the selectivity of a sedative for an anesthetic-sensitive receptor by determining the molar water solubility of the sedative. The invention further provides methods for modulating the selectivity of a sedative for an anesthetic-sensitive receptor by altering or modifying the sedative to have higher or lower water solubility. The invention further provides methods of inducing sedation in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods and at a vapor pressure less than 0.1 atm (76 mm Hg). | 2015-06-11 |
20150157597 | NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION - The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated neurodegenerative diseases. The neurodegenerative disease is treated using a JAK/STAT pathway inhibitor, including (-)-epigallocatechin-3-gallate (EGCG), to modulate JAK1 or STAT1 phosphorylation, resulting in resistance to gp120 or Tat neurotoxicity. The invention may be used to treat neurons afflicted with HIV-associated Dementia, multiple sclerosis, Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, or Pick's Disease, and may act in conjunction with antiviral treatment, like HAART. | 2015-06-11 |
20150157598 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 2015-06-11 |
20150157599 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 2015-06-11 |
20150157600 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 2015-06-11 |
20150157601 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 2015-06-11 |
20150157602 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 2015-06-11 |
20150157603 | NOVEL COMBINATION TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML) - The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML. | 2015-06-11 |
20150157604 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF PSYCHOLOGICAL, BEHAVIORAL AND COGNITIVE DISORDERS - The invention relates to the field of medicine and the pharmaceutical-chemical industry, and specifically, the field of neurology, and discloses compositions containing memantine and melatonin. It has been established that a strengthening of the effect of memantine takes place when it is combined with melatonin. The invention may be realized through the preparation of a finished pharmaceutical product such as capsules, preferably hard gelatin capsules. | 2015-06-11 |
20150157605 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders. | 2015-06-11 |
20150157606 | ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER - Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer. | 2015-06-11 |
20150157607 | Compounds that Enhance Atoh1 Expression - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 2015-06-11 |
20150157608 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS - The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC). | 2015-06-11 |
20150157609 | SOLID PREPARATION - The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the. active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. | 2015-06-11 |
20150157610 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATORY DISEASE - A pharmaceutical composition which comprises, as an active ingredient, a liposome encapsulating an immunosuppressant such as FK506, FTY720 and cyclosporin A is effective in the treatment of cardiovascular inflammatory diseases such as my ocardial infarction, myocarditis and vasculitis syndrome, allows the immunosuppressant at a low dose to produce stronger effects than those of the same dose of the immunosuppressant used alone, and causes fewer side effects. | 2015-06-11 |
20150157611 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME - The invention provides a novel compound having activity against diacylglycerol O-acyltransferase type 1 (DGAT1); a pharmaceutical composition for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 comprising said compound; a method for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 in an individual comprising administering said compound to the individual in need thereof; and a use of said compound for the manufacture of a medicament for preventing or treating a disease, disorder or condition modulated by DGAT1 inhibition. | 2015-06-11 |
20150157612 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 2015-06-11 |
20150157613 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R | 2015-06-11 |
20150157614 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID - Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions. | 2015-06-11 |
20150157616 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists - The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and/or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2015-06-11 |
20150157617 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA - Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1α) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1α prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1α. | 2015-06-11 |
20150157618 | Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof - Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same. | 2015-06-11 |
20150157619 | PHARMACEUTICAL PREPARATION FOR INJECTION - The present invention provides a preparation for injection comprising a protein with a molecular weight of 20 kDa or greater and a pyridine derivative, wherein the preparation for injection does not comprise a hydrophobic preservative. | 2015-06-11 |
20150157620 | LOZENGES WITH MULTIPLE RELEASE KINETICS FOR ACTIVE INGREDIENTS - The present invention relates to a film-coated lozenge intended to dissolve in the oral cavity, comprising a core comprising at least one active ingredient and at least one cooked sugar, and a shell comprising at least one layer comprising at least one active ingredient. | 2015-06-11 |
20150157621 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THE SAME - This therapeutic agent for chronic obstructive pulmonary disease comprises, an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I): | 2015-06-11 |
20150157622 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION - The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I). | 2015-06-11 |
20150157623 | COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION - The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell. | 2015-06-11 |
20150157624 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2015-06-11 |
20150157625 | METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 2015-06-11 |
20150157626 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS - Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject. | 2015-06-11 |
20150157628 | Pharmaceutical compositions of Lurasidone and Process for preparation thereof - Pharmaceutical compositions comprising an atypical antipsychotic as an active agent, process of preparation thereof and method of using the same are provided. Particularly the present invention relates to pharmaceutical compositions comprising lurasidone, process of preparation thereof and method to treat various psychotic disorders such as schizophrenia, positive and negative symptoms of schizophrenia, memory or learning dysfunctions caused by schizophrenia, senile dementia, attention deficit/hyperactivity disorder (ADHD), central nervous system (CNS) disorder responsive to modulation of glutamate levels, major depressive episodes associated with bipolar I disorder and other associated CNS disorders. | 2015-06-11 |
20150157629 | TYPE II RAF KINASE INHIBITORS - The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions. | 2015-06-11 |
20150157630 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO - The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer. | 2015-06-11 |
20150157631 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS - The present invention relates to the prophylaxis of acute noise-induced hearing loss by administering a compound of formula (I): wherein: W is group (Wa), group (Wb) or group (Wc): | 2015-06-11 |
20150157632 | SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHEN- YL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE - Solid pharmaceutical dosage forms comprising (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoate (telotristat) are disclosed, as well as methods of making them and compositions useful in their manufacture. | 2015-06-11 |
20150157633 | WNT PROTEIN SIGNALLING INHIBITORS - The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis. | 2015-06-11 |
20150157634 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE - Described herein are methods for treating and preventing alloantibody driven chronic graft versus host disease (cGVHD). The methods include administering to an individual in need thereof ibrutinib for treating and preventing alloantibody driven graft versus host disease. | 2015-06-11 |
20150157635 | Method Of Forming An Aerosol For Inhalation Delivery - The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. | 2015-06-11 |
20150157636 | METHODS FOR TREATING VIRAL DISORDERS - Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days. | 2015-06-11 |
20150157637 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): | 2015-06-11 |
20150157638 | Methods for Treating Parkinson's Disease - The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A | 2015-06-11 |
20150157639 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT - A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2015-06-11 |
20150157640 | NOVEL COMPOUNDS - Compounds of formula (I) | 2015-06-11 |
20150157641 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides a compound of Formula I: | 2015-06-11 |
20150157642 | COSMETIC METHOD FOR CHANGING THE APPEARANCE OF EYES - The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider appearance. Various methods involve application of one or more prostaglandins, synthetic prostaglandins, including synthetic prostaglandin F, and synthetic prostaglandin analogues, to eyelids, which results in contraction of eyelid muscles and a wider, more open appearance of the eyes. | 2015-06-11 |
20150157643 | METHOD FOR POST COITAL CONTRACEPTION IN OVERWEIGHT OR OBESE FEMALE SUBJECTS USING ULIPRISTAL ACETATE - The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese. | 2015-06-11 |
20150157644 | METHODS OF MAKING QUINOA LEACHATES AND USES THEREOF - The present application is directed to materials and method for producing leachates from a plant of the Amaranthaceae family. | 2015-06-11 |
20150157645 | COMBINATION OF A 17-ALPHA-HYDROXYLASE (C17,20-LYASE) INHIBITOR AND A SPECIFIC PI-3K INHIBITOR FOR TREATING A TUMOR DISEASE - The present invention relates to a combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of a compound of formula (I) or a compound of formula (II), or pharmaceutically acceptable salt thereof, (b) a 17α-Hydroxylase/C | 2015-06-11 |
20150157646 | Abiraterone Steroid Formulation - A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid. | 2015-06-11 |
20150157647 | METHODS AND COMPOSITIONS RELATED TO ACUTE RESPIRATORY DISTRESS SYNDROME - Certain embodiments are directed to methods of identifying patients with ARDS by detecting elevated levels of marinobufagenin (MBG) and treating the same with anti-MBG agents. | 2015-06-11 |
20150157648 | NUTRITIONAL APPROACH TO IMPROVING ATHLETIC PERFORMANCE AND REDUCING INJURY WITH L-ERGOTHIONEINE AND/OR VITAMIN D2 - Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and conditioning), and prevention and repair of injuries, including improving or maintaining muscle mitochondrial health, stimulating muscle mitochondrial biogenesis as well as other indications as set forth herein. In addition, pharmaceutical, nutraceutical and nutritional medical food compositions that are useful in conditions, normal or abnormal, associated with mitochondrial dysfunction and altered biogenesis in organ systems consisting of skeletal muscle, smooth muscle and cardiac muscle are also disclosed. L-Ergothioneine (also referred to as Ergothioneine or ET), Vitamin D2 (Ergocalciferol) and/or other antioxidants are disclosed for use in pharmaceutical, nutraceutical and nutritional medical food compositions for uses to stimulate production of bioactive molecules, including but not limited to glutathione, alpha synuclein, and IL-6. | 2015-06-11 |
20150157649 | LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE - Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis. | 2015-06-11 |